BRPI0517211B8 - composto, composição farmacêutica e seu uso. - Google Patents
composto, composição farmacêutica e seu uso.Info
- Publication number
- BRPI0517211B8 BRPI0517211B8 BRPI0517211A BRPI0517211A BRPI0517211B8 BR PI0517211 B8 BRPI0517211 B8 BR PI0517211B8 BR PI0517211 A BRPI0517211 A BR PI0517211A BR PI0517211 A BRPI0517211 A BR PI0517211A BR PI0517211 B8 BRPI0517211 B8 BR PI0517211B8
- Authority
- BR
- Brazil
- Prior art keywords
- allergic
- pharmaceutically acceptable
- heterocyclic compound
- reperfusion injury
- pharmaceutical composition
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Abstract
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US63723204P | 2004-12-17 | 2004-12-17 | |
IN1352/MUM/2004 | 2004-12-17 | ||
US60/637,232 | 2004-12-17 | ||
IN1352MU2004 | 2004-12-17 | ||
PCT/IB2005/003798 WO2006064355A2 (en) | 2004-12-17 | 2005-12-15 | Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders |
Publications (3)
Publication Number | Publication Date |
---|---|
BRPI0517211A BRPI0517211A (pt) | 2008-09-30 |
BRPI0517211B1 BRPI0517211B1 (pt) | 2020-08-11 |
BRPI0517211B8 true BRPI0517211B8 (pt) | 2021-05-25 |
Family
ID=36384379
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0517211A BRPI0517211B8 (pt) | 2004-12-17 | 2005-12-15 | composto, composição farmacêutica e seu uso. |
Country Status (19)
Country | Link |
---|---|
US (1) | US8129401B2 (pt) |
EP (1) | EP1831227B1 (pt) |
JP (1) | JP5122974B2 (pt) |
KR (1) | KR101317119B1 (pt) |
AP (1) | AP2334A (pt) |
AR (1) | AR066386A1 (pt) |
AU (1) | AU2005315319B2 (pt) |
BR (1) | BRPI0517211B8 (pt) |
CA (1) | CA2591438C (pt) |
EA (1) | EA014956B1 (pt) |
HK (1) | HK1111147A1 (pt) |
IL (1) | IL183827A (pt) |
MA (1) | MA29231B1 (pt) |
MX (1) | MX2007007345A (pt) |
MY (1) | MY143483A (pt) |
NZ (1) | NZ555809A (pt) |
PL (1) | PL1831227T3 (pt) |
TW (1) | TWI359814B (pt) |
WO (1) | WO2006064355A2 (pt) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008032171A1 (en) * | 2006-09-11 | 2008-03-20 | Matrix Laboratories Ltd. | Dibenzofuran derivatives as inhibitors of pde-4 and pde-10 |
RU2334514C1 (ru) * | 2006-12-01 | 2008-09-27 | Институт физиологически активных веществ Российской Академии наук | СРЕДСТВО ДЛЯ УЛУЧШЕНИЯ КОГНИТИВНЫХ ФУНКЦИЙ И ПАМЯТИ НА ОСНОВЕ ГИДРИРОВАННЫХ ПИРИДО (4,3-b) ИНДОЛОВ (ВАРИАНТЫ), ФАРМАКОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ И СПОСОБ ЕГО ПРИМЕНЕНИЯ |
WO2008081282A2 (en) * | 2006-12-20 | 2008-07-10 | Glenmark Pharmaceuticals S.A. | Process for the synthesis of n9-(3,5-dichloro-4-pyridyl)-6- difluoromethoxybenzo(4,5)furo(3,2-c)pyridine-9-carboxamide and salts thereof |
US20110160213A1 (en) * | 2007-02-01 | 2011-06-30 | Glenmark Pharmaceuticals, S.A. | Pharmaceutical compositions for the treatment of inflammatory and allergic disorders |
WO2008142542A2 (en) * | 2007-05-22 | 2008-11-27 | Glenmark Pharmaceuticals, S.A. | Processes for preparing benzofuro [3, 2-c] pyridine- 9-carbaldehyde derivatives as novel intermediates for the synthesis of pde iv inhibitors |
RU2007139634A (ru) * | 2007-10-25 | 2009-04-27 | Сергей Олегович Бачурин (RU) | Новые тиазол-, триазол- или оксадиазол-содержащие тетрациклические соединения |
CN101910131B (zh) | 2007-11-16 | 2014-04-23 | 里格尔药品股份有限公司 | 甲酰胺、磺酰胺和胺化合物及其使用方法 |
WO2009076631A1 (en) | 2007-12-12 | 2009-06-18 | Rigel Pharmaceuticals, Inc. | Carboxamide, sulfonamide and amine compounds for metabolic disorders |
EP2070913A1 (en) | 2007-12-14 | 2009-06-17 | CHIESI FARMACEUTICI S.p.A. | Ester derivatives as phosphodiesterase inhibitors |
AU2009204048B2 (en) | 2008-01-11 | 2013-08-01 | Albany Molecular Research, Inc. | (1-azinone) -substituted pyridoindoles as MCH antagonists |
JP5658138B2 (ja) | 2008-04-23 | 2015-01-21 | ライジェル ファーマシューティカルズ, インコーポレイテッド | 代謝障害の処置のためのカルボキサミド化合物 |
KR20120034592A (ko) | 2009-04-09 | 2012-04-12 | 베링거 인겔하임 인터내셔날 게엠베하 | Hiv 복제의 저해제 |
US9255094B2 (en) | 2009-04-29 | 2016-02-09 | Medivation Technologies, Inc. | Pyrido[4,3-B]indoles and methods of use |
CA2760516A1 (en) | 2009-04-29 | 2011-02-17 | Medivation Technologies, Inc. | Pyrido[4,3-b]indoles and methods of use |
US8637501B2 (en) | 2009-07-01 | 2014-01-28 | Albany Molecular Research, Inc. | Azinone-substituted azepino[b]indole and pyrido-pyrrolo-azepine MCH-1 antagonists, methods of making, and use thereof |
US8629158B2 (en) | 2009-07-01 | 2014-01-14 | Albany Molecular Research, Inc. | Azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine MCH-1 antagonists, methods of making, and use thereof |
US9073925B2 (en) | 2009-07-01 | 2015-07-07 | Albany Molecular Research, Inc. | Azinone-substituted azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine MCH-1 antagonists, methods of making, and use thereof |
WO2011003012A1 (en) | 2009-07-01 | 2011-01-06 | Albany Molecular Research, Inc. | Azinone-substituted azapolycycle mch-1 antagonists, methods of making, and use thereof |
US8575186B2 (en) | 2009-10-05 | 2013-11-05 | Albany Molecular Research, Inc. | Epiminocycloalkyl[b] indole derivatives as serotonin sub-type 6 (5-HT6) modulators and uses thereof |
WO2011132051A2 (en) * | 2010-04-19 | 2011-10-27 | Glenmark Pharmaceuticals S.A. | Tricycle compounds as phosphodiesterase-10 inhibitors |
PT2585469T (pt) * | 2010-06-24 | 2016-08-29 | Leo Pharma As | Compostos heterocíclicos de benzodioxolo ou benzodioxepina como inibidores da fosfodiesterase |
WO2012088038A2 (en) | 2010-12-21 | 2012-06-28 | Albany Molecular Research, Inc. | Piperazinone-substituted tetrahydro-carboline mch-1 antagonists, methods of making, and uses thereof |
WO2012088124A2 (en) | 2010-12-21 | 2012-06-28 | Albany Molecular Research, Inc. | Tetrahydro-azacarboline mch-1 antagonists, methods of making, and uses thereof |
WO2012098495A1 (en) | 2011-01-19 | 2012-07-26 | Glenmark Pharmaceuticals Sa | Pharmaceutical composition that includes revamilast and a beta-2 agonist |
US9067949B2 (en) | 2011-01-19 | 2015-06-30 | Albany Molecular Research, Inc. | Benzofuro[3,2-c] pyridines and related analogs as serotonin sub-type 6 (5-HT6) modulators for the treatment of obesity, metabolic syndrome, cognition and schizophrenia |
WO2012110946A1 (en) | 2011-02-17 | 2012-08-23 | Glenmark Pharmaceuticals Sa | Pharmaceutical composition comprising the pde4 enzyme inhibitor revamilast and a disease modifying agent, preferably methotrexate |
AU2012254158B2 (en) | 2011-02-18 | 2016-02-04 | Medivation Technologies, Inc. | Compounds and methods of treating diabetes |
WO2012168907A1 (en) | 2011-06-10 | 2012-12-13 | Glenmark Pharmaceuticals Sa | Pharmaceutical composition comprising revamilast and montelukast or zafirlukast |
WO2013084182A1 (en) | 2011-12-08 | 2013-06-13 | Glenmark Pharmaceuticals S.A. | Pharmaceutical composition that includes a pde4 enzyme inhibitor and an analgesic agent |
BR112015023328A2 (pt) | 2013-03-13 | 2017-07-18 | Flatley Discovery Lab | compostos de piridazinona e métodos para o tratamento de fibrose cística |
TWI648272B (zh) | 2013-06-25 | 2019-01-21 | 美商必治妥美雅史谷比公司 | 經取代之四氫咔唑及咔唑甲醯胺化合物 |
SG11201510028PA (en) | 2013-06-25 | 2016-01-28 | Bristol Myers Squibb Co | Carbazole carboxamide compounds useful as kinase inhibitors |
CN107108555B (zh) | 2014-10-24 | 2020-12-01 | 百时美施贵宝公司 | 三环阻转异构体化合物 |
KR102514914B1 (ko) | 2014-10-24 | 2023-03-27 | 브리스톨-마이어스 스큅 컴퍼니 | 카르바졸 유도체 |
AR102426A1 (es) | 2014-10-24 | 2017-03-01 | Bristol Myers Squibb Co | Compuestos de indolcarboxamida como inhibidores de btk |
CN106496322A (zh) * | 2015-09-07 | 2017-03-15 | 江苏恒瑞医药股份有限公司 | 人胰岛素或其类似物的酰化衍生物的制备方法 |
JP6472428B2 (ja) * | 2015-12-09 | 2019-02-20 | 財團法人食品工業發展研究所 | キサンチンオキシダーゼ活性の阻害におけるβ−カルボリンアルカロイドの使用 |
CN112979667B (zh) * | 2019-12-02 | 2022-04-22 | 首都医科大学 | 二氧六环修饰的四氢咔啉-3-甲酰-The,其合成,活性和应用 |
CN112898376B (zh) * | 2019-12-02 | 2022-06-24 | 首都医科大学 | 二氧六环修饰的四氢咔啉-3-甲酰-The-HGK,其制备,抗肿瘤活性和应用 |
Family Cites Families (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1041861A (en) | 1962-03-14 | 1966-09-07 | Organon Labor Ltd | Pyrrolidone derivatives and pharmaceutical preparations containing them |
US3759948A (en) | 1969-06-25 | 1973-09-18 | Merck & Co Inc | Non-steroid anti-inflammatory compounds |
NL7008628A (pt) | 1969-06-25 | 1970-12-29 | ||
NL7016899A (pt) | 1969-12-03 | 1971-06-07 | ||
US3846553A (en) | 1969-12-03 | 1974-11-05 | Merck & Co Inc | 3-substituted-2-pyridones in the treatment of pain, fever or inflammation |
US4222944A (en) | 1978-07-31 | 1980-09-16 | Hoffmann-La Roche Inc. | Halo-3-dibenzofuran alkanonitriles |
JPS62158253A (ja) | 1985-12-28 | 1987-07-14 | Kirin Brewery Co Ltd | 4−アミノピリジンアミド誘導体 |
JPH0812430B2 (ja) | 1986-07-07 | 1996-02-07 | キヤノン株式会社 | 電子写真感光体 |
EP0257956B2 (en) | 1986-08-19 | 2000-11-22 | Genentech, Inc. | Use of polypeptide growth factors and cytokines for the manufacture of a device and of a dispersion |
JPS63250378A (ja) * | 1987-04-07 | 1988-10-18 | Mitsubishi Kasei Corp | インド−ル誘導体 |
US5202344A (en) | 1990-12-11 | 1993-04-13 | G. D. Searle & Co. | N-substituted lactams useful as cholecystokinin antagonists |
IE71647B1 (en) | 1991-01-28 | 1997-02-26 | Rhone Poulenc Rorer Ltd | Benzamide derivatives |
WO1993019747A1 (en) | 1992-04-02 | 1993-10-14 | Smithkline Beecham Corporation | Compounds useful for treating allergic and inflammatory diseases |
CA2140441C (en) | 1992-07-28 | 2006-11-21 | Garry Fenton | Inhibitors of c-amp phosphodiesterase and tnf |
MX9306311A (es) | 1992-10-13 | 1994-04-29 | Smithkline Beecham Plc | Compuestos antagonistas del receptor de 5-ht4, procedimiento para su preparacion y composiciones farmaceuticas que los contienen |
US5814651A (en) | 1992-12-02 | 1998-09-29 | Pfizer Inc. | Catechol diethers as selective PDEIV inhibitors |
GB9304920D0 (en) | 1993-03-10 | 1993-04-28 | Celltech Ltd | Chemical compounds |
CZ290266B6 (cs) | 1993-07-02 | 2002-06-12 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Substituované benzamidy, způsob jejich výroby a farmaceutické prostředky s jejich obsahem |
GB9315595D0 (en) | 1993-07-28 | 1993-09-08 | Res Inst Medicine Chem | New compounds |
WO1995009837A1 (en) | 1993-10-01 | 1995-04-13 | Smithkline Beecham Corporation | Cyano compounds |
GB9401460D0 (en) | 1994-01-26 | 1994-03-23 | Rhone Poulenc Rorer Ltd | Compositions of matter |
GB9404706D0 (en) | 1994-03-11 | 1994-04-27 | Smithkline Beecham Corp | Compounds |
CA2196046A1 (en) | 1994-07-27 | 1996-02-08 | Nigel Birdsall | Heterocyclic compounds, useful as allosteric effectors at muscarinic receptors |
CA2361954C (en) | 1995-04-14 | 2003-07-08 | Smithkline Beecham Corporation | Metered dose inhaler for albuterol |
US6514996B2 (en) * | 1995-05-19 | 2003-02-04 | Kyowa Hakko Kogyo Co., Ltd. | Derivatives of benzofuran or benzodioxole |
DE19616573C2 (de) | 1996-04-25 | 1999-03-04 | Pari Gmbh | Verwendung unterkritischer Treibmittelmischungen und Aerosole für die Mikronisierung von Arzneimitteln mit Hilfe dichter Gase |
WO1998009934A1 (en) | 1996-09-04 | 1998-03-12 | Warner-Lambert Company | Matrix metalloproteinase inhibitors and their therapeutic uses |
US6177440B1 (en) * | 1996-10-30 | 2001-01-23 | Eli Lilly And Company | Substituted tricyclics |
JP3530004B2 (ja) | 1998-02-06 | 2004-05-24 | 株式会社日立ユニシアオートモティブ | 吸入式投薬器 |
DE69939689D1 (de) | 1998-03-19 | 2008-11-20 | Vertex Pharma | Caspase inhibitoren |
US6110962A (en) | 1998-05-12 | 2000-08-29 | American Home Products Corporation | 11-aryl-benzo[B]naphtho[2,3-D]furans and 11-aryl-benzo[B]naphtho[2,3-D]thiophenes useful in the treatment of insulin resistance and hyperglycemia |
JP2002514638A (ja) | 1998-05-12 | 2002-05-21 | アメリカン・ホーム・プロダクツ・コーポレイション | インスリン抵抗性および高血糖症の治療に有用な11−アリール−ベンゾ[b]ナフト[2,3−d]フラン類および11−アリール−ベンゾ[b]ナフト[2,3−d]チオフェン類 |
US6887870B1 (en) | 1999-10-12 | 2005-05-03 | Bristol-Myers Squibb Company | Heterocyclic sodium/proton exchange inhibitors and method |
BR0109467A (pt) | 2000-03-17 | 2003-06-03 | Bristol Myers Squibb Pharma Co | Composto derivados de (beta)-aminoácidos cìclicos, composição farmacêutica, método de tratamento de condições ou doenças mediadas por mps, tnf, aggrecanase ou uma combinação destes em mamìferos e uso de composto |
DE60125026T2 (de) | 2000-03-23 | 2007-06-28 | Takeda Pharmaceutical Co. Ltd. | Fluorisochinolinderivate, verfahren zu ihrer herstellung und ihre anwendung |
AU2002228316A1 (en) | 2001-01-29 | 2002-08-12 | Insight Strategy And Marketing Ltd | Carbazole derivatives and their uses as heparanase inhibitors |
US20020128920A1 (en) | 2001-03-06 | 2002-09-12 | Dilip Chopra | System and method for providing lowest costs purchasing |
AU2002306687A1 (en) | 2001-03-13 | 2002-09-24 | Glenmark Pharmaceuticals Limited | Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them |
AU2003253130A1 (en) | 2002-08-19 | 2004-03-03 | Glenmark Pharmaceuticals Limited | Condensed heterocyclic compounds as pde-iv inhibitors for the treatment of inflammatory and allergic disorders |
WO2004022536A1 (en) | 2002-09-04 | 2004-03-18 | Glenmark Pharmaceuticals Limited | New heterocyclic amide compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them |
BR0314721A (pt) * | 2002-10-23 | 2005-08-02 | Glenmark Pharmaceuticals Ltd | Compostos tricìclicos úteis para tratamento de distúrbios inflamatórios e alérgicos, processo para sua preparação e composições farmacêuticas contendo-os |
WO2004069831A1 (en) * | 2003-02-10 | 2004-08-19 | Glenmark Pharmaceuticals Ltd. | Tricyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation |
DE602004020332D1 (de) | 2003-04-11 | 2009-05-14 | Glenmark Pharmaceuticals Sa | Neue heterozyklische verbindungen, die sich für die behandlung von entzündlichen und allergischen erkrankungen eignen: verfahren zu deren herstellung und pharmazeutische zusammensetzungen, die diese enthalten |
-
2005
- 2005-12-15 MX MX2007007345A patent/MX2007007345A/es active IP Right Grant
- 2005-12-15 KR KR1020077014219A patent/KR101317119B1/ko not_active IP Right Cessation
- 2005-12-15 EP EP05826587.7A patent/EP1831227B1/en active Active
- 2005-12-15 AP AP2007004031A patent/AP2334A/xx active
- 2005-12-15 CA CA2591438A patent/CA2591438C/en active Active
- 2005-12-15 NZ NZ555809A patent/NZ555809A/en not_active IP Right Cessation
- 2005-12-15 JP JP2007546221A patent/JP5122974B2/ja active Active
- 2005-12-15 AR ARP050105281A patent/AR066386A1/es unknown
- 2005-12-15 BR BRPI0517211A patent/BRPI0517211B8/pt active IP Right Grant
- 2005-12-15 EA EA200701268A patent/EA014956B1/ru not_active IP Right Cessation
- 2005-12-15 PL PL05826587T patent/PL1831227T3/pl unknown
- 2005-12-15 AU AU2005315319A patent/AU2005315319B2/en not_active Ceased
- 2005-12-15 WO PCT/IB2005/003798 patent/WO2006064355A2/en active Application Filing
- 2005-12-16 TW TW094144699A patent/TWI359814B/zh not_active IP Right Cessation
- 2005-12-16 MY MYPI20055953A patent/MY143483A/en unknown
-
2007
- 2007-06-10 IL IL183827A patent/IL183827A/en not_active IP Right Cessation
- 2007-07-12 MA MA30075A patent/MA29231B1/fr unknown
-
2008
- 2008-02-18 HK HK08101735.0A patent/HK1111147A1/xx not_active IP Right Cessation
-
2011
- 2011-04-15 US US13/087,826 patent/US8129401B2/en active Active - Reinstated
Also Published As
Publication number | Publication date |
---|---|
KR101317119B1 (ko) | 2013-10-11 |
KR20070100254A (ko) | 2007-10-10 |
AU2005315319A1 (en) | 2006-06-22 |
BRPI0517211B1 (pt) | 2020-08-11 |
JP5122974B2 (ja) | 2013-01-16 |
HK1111147A1 (en) | 2008-08-01 |
AU2005315319B2 (en) | 2011-07-07 |
TWI359814B (en) | 2012-03-11 |
PL1831227T3 (pl) | 2013-10-31 |
CA2591438C (en) | 2014-04-29 |
EA200701268A1 (ru) | 2007-12-28 |
US8129401B2 (en) | 2012-03-06 |
EP1831227A2 (en) | 2007-09-12 |
JP2008524201A (ja) | 2008-07-10 |
CA2591438A1 (en) | 2006-06-22 |
US20110190303A1 (en) | 2011-08-04 |
AR066386A1 (es) | 2009-08-19 |
NZ555809A (en) | 2010-07-30 |
BRPI0517211A (pt) | 2008-09-30 |
MY143483A (en) | 2011-05-31 |
MA29231B1 (fr) | 2008-02-01 |
AP2334A (en) | 2011-12-06 |
TW200634015A (en) | 2006-10-01 |
IL183827A0 (en) | 2007-09-20 |
EP1831227B1 (en) | 2013-06-19 |
IL183827A (en) | 2013-02-28 |
AP2007004031A0 (en) | 2007-06-30 |
WO2006064355A2 (en) | 2006-06-22 |
EA014956B1 (ru) | 2011-04-29 |
WO2006064355A3 (en) | 2006-08-03 |
MX2007007345A (es) | 2007-09-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0517211B8 (pt) | composto, composição farmacêutica e seu uso. | |
EP4031249A1 (en) | 4-substituted indole and indazole sulfonamido derivatives as parg inhibitors | |
TNSN07251A1 (en) | 2-phenyl-indoles as prostaglandin d2 receptor antagonists | |
TNSN08339A1 (en) | 2,6 -substituted-4-monosubstituted amino-pyrimidine as prostaglandin d2 receptor antagonists | |
WO2005021515A3 (en) | Inhibitors of phosphodiesterase type-iv | |
MX2010004819A (es) | Derivados de [1h-pirazolo[3,4-b]piridin-4-il]-fenilo o piridin-2-ilo como proteina cinasa c-theta. | |
NO20065948L (no) | Quinazolin-4-yl-piperidin- and cinnolin-4-yl-piperidin-derivatives som PDE10-inhibitorer for behandling av CNS forstyrrelser | |
NO20055316L (no) | Nye heterocykliske forbindelser som er nyttige ved behandling av inflammatoriske og allergiske forstyrrelser, fremgangsmate for fremstilling derav og farmasoytiske sammensetninger som inneholder slike | |
NO20051826L (no) | Heterosyklisk substituerte piperaziner for behandling av schizofreni | |
US20080227797A1 (en) | Pyridopyrimidine Derivatives as Pde4 Inhibitors for the Treatment of Inflammatory and Immune Diseases | |
JP2017513954A (ja) | Irak阻害剤およびその使用 | |
ECSP067058A (es) | Nuevos derivados de piridazin-3(2h)-ona | |
SA07280646B1 (ar) | مشتقات هيدانتوين جديدة وعمليات لتحضيرها وتركيبات صيدلانية تحتوي عليها واستخدامها | |
BRPI0612888A2 (pt) | anilino-piridinotriazinas cìclicas como inibidoras de gsk-3, seus usos e composição farmacêutica, intermediário, seu uso e composição farmacêutica | |
CA2987019A1 (en) | Pyrido[3,4-d]pyrimidine derivative and pharmaceutically acceptable salt thereof | |
EA200900472A1 (ru) | Ингибиторы фосфодиэстеразы iv типа | |
UA88795C2 (ru) | Гетероциклические соединения, которые применяются для лечения воспалителных и аллергических нарушений | |
AR062051A1 (es) | 2-fenilindoles como antagonistas del receptor de la prostaglandina d₂ | |
CA2906262A1 (en) | Macrocyclic salt-inducible kinase inhibitors | |
WO2008002596A3 (en) | Adenosine a2a receptor antagonists | |
WO2010084402A3 (en) | Heterocyclic compounds as phosphodiesterase inhibitors | |
NO20091577L (no) | Nye 5,7-disubstituerte (1,3)tiazolo[4,5-D]pyrimidin-2(3H)-aminderivater og deres anvendelse i terapi | |
WO2005051931A3 (en) | Phosphodiesterase inhibitors | |
AU2015359562B2 (en) | Piperidine substituted tricyclic pyrazolo[1,5-a]pyrimidine derivatives with inhibitory activity on the replication of the respiratory syncytial virus (RSV) | |
US20220024931A1 (en) | SELECTIVE PI3Kdelta INHIBITOR AND USE THEREOF |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B06I | Publication of requirement cancelled [chapter 6.9 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 6.21 NA RPI NO 2562 DE 11/02/2020 POR TER SIDO INDEVIDA. |
|
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 11/08/2020, OBSERVADAS AS CONDICOES LEGAIS. |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 15/12/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |